Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
View Patent ↗The disclosures herein relate generally to acyloxyalkyl carbamate prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, pharmaceutical compositions thereof, methods of making prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, methods of using prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, and pharmaceutical compositions thereof for treating or preventing common diseases and/or disorders such as spasticity and/or acid reflux disease. The disclosures herein also relate to acyloxyalkyl carbamate prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof which are suitable for oral administration and to sustained release oral dosage forms thereof.
1. A method of treating or preventing spasticity comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
R 1 is selected from the group consisting of acyl, substituted acyl, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl and substituted heteroarylalkyl;
R 2 and R 3 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkoxycarbonyl, substituted alkoxycarbonyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl and substituted heteroarylalkyl or optionally, R 2 and R 3 together with the carbon atom to which they are bonded form a cycloalkyl, substituted cycloalkyl, cycloheteroalkyl or substituted cycloheteroalkyl ring;
R 4 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, aryldialkylsilyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl or trialkylsilyl; and
R 5 is selected from the group consisting of substituted aryl, heteroaryl and substituted heteroaryl.
2. A method of treating or preventing spasticity comprising administering to a patient in need of such treatment or prevention a pharmaceutical composition comprising a therapeutically effective amount of the compound of Formula (I) or a pharmaceutically acceptable salt thereof according to claim 1 and a pharmaceutically acceptable vehicle.
3. The method of claim 2 , wherein the composition comprises an oral dosage form.
4. The method of claim 3 , wherein the oral dosage form is a sustained release oral dosage form.
5. The method of claim 4 , wherein the dosage form is adapted to be swallowed by a patient in order to introduce the dosage form into an intestinal lumen of the patient; the dosage form further being adapted to release the compound of Formula (I) gradually into the intestinal lumen of the patient over a period of hours after said swallowing, the gradual release causing the compound of Formula (I) to be cleaved after said swallowing to provide a therapeutic concentration the compound of Formula (I) in the plasma of the patient.
6. The method of claim 5 wherein the period of hours comprises at least about 6 hours.
7. The method of claim 5 , wherein the period of hours comprises at least about 8 hours.
8. The method of claim 5 , wherein the period of hours comprises at least about 12 hours.
9. A method of treating or preventing gastro-esophageal reflux disease comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
R 1 is selected from the group consisting of acyl, substituted acyl, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl and substituted heteroarylalkyl;
R 2 and R 3 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkoxycarbonyl, substituted alkoxycarbonyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl and substituted heteroarylalkyl or optionally, R 2 and R 3 together with the carbon atom to which they are bonded form a cycloalkyl, substituted cycloalkyl, cycloheteroalkyl or substituted cycloheteroalkyl ring;
R 4 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, aryldialkylsilyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl or trialkylsilyl; and
R 5 is selected from the group consisting of substituted aryl, heteroaryl and substituted heteroaryl.
10. A method of treating or preventing gastro-esophageal reflux disease comprising administering to the patient in need of such treatment or prevention a pharmaceutical composition comprising a therapeutically effective amount of the compound of Formula (I) or a pharmaceutically acceptable salt thereof according to claim 9 and a pharmaceutically acceptable vehicle.
11. The method of claim 10 , wherein the composition comprises an oral dosage form.
12. The method of claim 11 , wherein the oral dosage form is a sustained release oral dosage form.
13. The method of claim 12 , wherein the dosage form is adapted to be swallowed by a patient in order to introduce the dosage form into an intestinal lumen of the patient; the dosage form further being adapted to release the compound of Formula (I) gradually into the intestinal lumen of the patient over a period of hours after said swallowing, the gradual release causing the compound of Formula (I) to be cleaved after said swallowing to provide a therapeutic concentration the compound of Formula (I) in the plasma of the patient.
14. The method of claim 13 wherein the period of hours comprises at least about 6 hours.
15. The method of claim 13 , wherein the period of hours comprises at least about 8 hours.
16. The method of claim 13 , wherein the period of hours comprises at least about 12 hours.
17. A method of treating or preventing drug abuse or addiction comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
R 1 is selected from the group consisting of acyl, substituted acyl, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl and substituted heteroarylalkyl;
R 2 and R 3 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkoxycarbonyl, substituted alkoxycarbonyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl and substituted heteroarylalkyl or optionally, R 2 and R 3 together with the carbon atom to which they are bonded form a cycloalkyl, substituted cycloalkyl, cycloheteroalkyl or substituted cycloheteroalkyl ring;
R 4 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, aryldialkylsilyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl or trialkylsilyl; and
R 5 is selected from the group consisting of substituted aryl, heteroaryl and substituted heteroaryl.
18. The method of claim 17 , wherein the drug is selected from the group consisting of alcohol, nicotine, and narcotics.
19. A method of treating drug abuse or addiction comprising administering to a patient in need of such treatment or prevention a pharmaceutical composition comprising a therapeutically effective amount of the compound of Formula (I) or a pharmaceutically acceptable salt thereof according to claim 17 and a pharmaceutically acceptable vehicle.
20. The method of claim 19 , wherein the composition comprises an oral dosage form.
21. The method of claim 20 , wherein the oral dosage form is a sustained release oral dosage form.
22. The method of claim 21 , wherein the dosage form is adapted to be swallowed by a patient in order to introduce the dosage form into an intestinal lumen of the patient; the dosage form further being adapted to release the compound of Formula (I) gradually into the intestinal lumen of the patient over a period of hours after said swallowing, the gradual release causing the compound of Formula (I) to be cleaved after said swallowing to provide a therapeutic concentration the compound of Formula (I) in the plasma of the patient.
23. The method of claim 22 wherein the period of hours comprises at least about 6 hours.
24. The method of claim 22 , wherein the period of hours comprises at least about 8 hours.
25. The method of claim 22 , wherein the period of hours comprises at least about 12 hours.